Ocular Therapeutix (OCUL) News Today

Aptus Capital Advisors LLC purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 262,810 shares of the biopharmace

Banco Santander S.A. lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 81.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 377,368 shares of the biopharmaceutical company's stock aft

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Sanjay Nayak sold 1,832 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $9.02, for a total transaction of $16,524.64. Following the completion of the transaction, the insider now directly owns 176,194 shares of the company's stock, valued at $1,589,269.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ocular Therapeutix (NASDAQ:OCUL) Shares Up 4.6%

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating t

Deltec Asset Management LLC increased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 9.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,590,265 shares of the biopharm

Ocular Therapeutix (NASDAQ:OCUL) Trading Down 4%

Robert W. Baird reduced their price target on shares of Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating on the stock in a research report on Thursday.

Vanguard Group Inc. lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 41.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,235,131 shares of the biopharmaceutical company's stock

Price T Rowe Associates Inc. MD grew its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1,142.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 662,672

Cetera Advisors LLC lifted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1,455.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 723,490 shares of the biopharmac

Ocular Therapeutix (NASDAQ:OCUL) will be releasing earnings before the market opens on Wednesday, August 7, Zacks reports.

HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of Ocular Therapeutix in a research note on Thursday.

Banco Santander S.A. trimmed its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 61.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 208,196 shares of the biopharmaceutical company's stock after selling 3

BNP Paribas Financial Markets increased its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 373.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 185,308 shares of the bi

Ocular Therapeutix (NASDAQ:OCUL) Trading Up 5.7%

Ocular Therapeutix (NASDAQ:OCUL) Trading Down 4.1%

TD Cowen downgraded Ocular Therapeutix from a "strong-buy" rating to a "hold" rating in a research report on Friday.

Ocular Therapeutix (NASDAQ:OCUL) Trading Up 6.1%

Piper Sandler reaffirmed an "overweight" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Friday.

TD Cowen upgraded Ocular Therapeutix from a "hold" rating to a "buy" rating and increased their price objective for the company from $7.00 to $11.00 in a report on Thursday.